CO5130004A1 - 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas - Google Patents

1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas

Info

Publication number
CO5130004A1
CO5130004A1 CO99051075A CO99051075A CO5130004A1 CO 5130004 A1 CO5130004 A1 CO 5130004A1 CO 99051075 A CO99051075 A CO 99051075A CO 99051075 A CO99051075 A CO 99051075A CO 5130004 A1 CO5130004 A1 CO 5130004A1
Authority
CO
Colombia
Prior art keywords
alkyl
amino
carboxy
hydroxy
aminosulfonyl
Prior art date
Application number
CO99051075A
Other languages
English (en)
Inventor
Edward Fox Kleinman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5130004A1 publication Critical patent/CO5130004A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula:<EMI FILE="99051075_1" ID="1" IMF=JPEG >o la sal farmacéuticamente aceptable del mismo; en la que cada uno de R1 y R2 se selecciona, independientemente, entre el grupo compuesto por hidrógeno, alquilo (C1-C6), cicloalquilo (C3-C7), arilo (C6-C10), heteroarilo (C5-C9) y heterocicloalquilo (C2-C9), donde los grupos alquilo, cicloalquilo, arilo, heteroarilo o heterocicloalquilo están opcionalmente sustituidos con halo, hidroxi, alquilo (C1-C6), alcoxi (C1-C6), amino, alquilamino (C1-C6), (alquil(C1-C6))2-amino, tio, alquiltio (C1-C6), ciano, carboxi, carboxi- alquilo (C1-C6), hidroxi-alquilo (C1-C6), acilo (C1-C6), aminosulfonilo, alquilaminosulfonilo (C1-C6) o (alquil(C1-C6))2aminosulfonilo; y R3 es hidrógeno, halo, hidroxi, alquilo (C1-C6), alcoxi (C1-C6), amino, alquilamino (C1-C6), (alquil(C1-C6))2amino, tio, alquiltio (C1-C6), carboxi, carboxi-alquilo (C1-C6), hidroxi-alquilo (C1-C6), acilo (C1-C6), aminosulfonilo, alquilaminosulfonilo (C1-C6) o (alquil(C1-C6))2-aminosulfonilo.
CO99051075A 1998-08-11 1999-08-11 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas CO5130004A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9617698P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
CO5130004A1 true CO5130004A1 (es) 2002-02-27

Family

ID=22256080

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99051075A CO5130004A1 (es) 1998-08-11 1999-08-11 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas

Country Status (44)

Country Link
US (1) US6174895B1 (es)
EP (1) EP1104420B1 (es)
JP (1) JP2002522541A (es)
KR (1) KR20010072368A (es)
CN (1) CN1312810A (es)
AP (1) AP2001002068A0 (es)
AR (1) AR015557A1 (es)
AT (1) ATE229955T1 (es)
AU (1) AU4924999A (es)
BG (1) BG105321A (es)
BR (1) BR9912902A (es)
CA (1) CA2340180A1 (es)
CO (1) CO5130004A1 (es)
CZ (1) CZ2001485A3 (es)
DE (1) DE69904602T2 (es)
DK (1) DK1104420T3 (es)
DZ (1) DZ2866A1 (es)
EA (1) EA200100124A1 (es)
EE (1) EE200100085A (es)
ES (1) ES2188194T3 (es)
GE (1) GEP20033029B (es)
GT (1) GT199900128A (es)
HK (1) HK1038917A1 (es)
HN (1) HN1999000130A (es)
HR (1) HRP20010107A2 (es)
HU (1) HUP0103466A3 (es)
ID (1) ID27843A (es)
IL (1) IL140868A0 (es)
IS (1) IS5815A (es)
MA (1) MA26669A1 (es)
NO (1) NO20010684L (es)
NZ (1) NZ509297A (es)
OA (1) OA11591A (es)
PA (1) PA8480001A1 (es)
PE (1) PE20000950A1 (es)
PL (1) PL346005A1 (es)
PT (1) PT1104420E (es)
SK (1) SK1822001A3 (es)
SV (1) SV1999000120A (es)
TN (1) TNSN99155A1 (es)
TR (1) TR200100433T2 (es)
TW (1) TW542835B (es)
WO (1) WO2000009504A1 (es)
ZA (1) ZA200101040B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
AU2002241596A1 (en) * 2000-11-02 2002-06-18 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
WO2003077850A2 (en) 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
KR100454750B1 (ko) * 2002-06-20 2004-11-03 삼성에스디아이 주식회사 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자
EP1567136A1 (en) * 2002-11-27 2005-08-31 ALTANA Pharma AG Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10349497A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag N-substituierte Pyrazolylcarboxanilide
WO2005067935A1 (de) * 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
SG11201500732TA (en) * 2012-08-08 2015-02-27 Merck Patent Gmbh (aza-)isoquinolinone derivatives
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU165405B (es) * 1972-06-29 1974-08-28
US3856800A (en) * 1973-02-26 1974-12-24 Sterling Drug Inc Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates
US3882132A (en) * 1973-03-08 1975-05-06 Sterling Drug Inc Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs
WO1996006843A1 (fr) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de naphtyridine et composition medicinale a base de ce derive
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤

Also Published As

Publication number Publication date
GEP20033029B (en) 2003-07-25
WO2000009504A1 (en) 2000-02-24
SV1999000120A (es) 2000-09-05
ZA200101040B (en) 2003-01-07
CZ2001485A3 (cs) 2002-05-15
CA2340180A1 (en) 2000-02-24
TW542835B (en) 2003-07-21
ATE229955T1 (de) 2003-01-15
OA11591A (en) 2004-07-30
BR9912902A (pt) 2001-05-08
TNSN99155A1 (fr) 2005-11-10
EP1104420B1 (en) 2002-12-18
DE69904602D1 (en) 2003-01-30
HN1999000130A (es) 2000-11-22
NO20010684D0 (no) 2001-02-09
SK1822001A3 (en) 2002-08-06
IS5815A (is) 2001-01-16
AP2001002068A0 (en) 2001-03-31
BG105321A (en) 2001-12-29
PT1104420E (pt) 2003-03-31
KR20010072368A (ko) 2001-07-31
ES2188194T3 (es) 2003-06-16
IL140868A0 (en) 2002-02-10
HUP0103466A3 (en) 2002-11-28
HRP20010107A2 (en) 2002-02-28
AU4924999A (en) 2000-03-06
EP1104420A1 (en) 2001-06-06
TR200100433T2 (tr) 2001-07-23
JP2002522541A (ja) 2002-07-23
NO20010684L (no) 2001-04-09
EA200100124A1 (ru) 2001-10-22
MA26669A1 (fr) 2004-12-20
DK1104420T3 (da) 2003-01-13
CN1312810A (zh) 2001-09-12
ID27843A (id) 2001-04-26
PL346005A1 (en) 2002-01-14
NZ509297A (en) 2003-11-28
HUP0103466A2 (hu) 2002-02-28
DE69904602T2 (de) 2003-04-30
DZ2866A1 (fr) 2003-12-01
AR015557A1 (es) 2001-05-02
EE200100085A (et) 2002-08-15
PE20000950A1 (es) 2000-09-27
GT199900128A (es) 2001-01-30
US6174895B1 (en) 2001-01-16
HK1038917A1 (zh) 2002-04-04
PA8480001A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
CO5130004A1 (es) 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas
CO5390075A1 (es) Derivados de pirrilidinona
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CO5271665A1 (es) (compuestos de pirrolo [2,3-d] pirimidina
DE3781716D1 (de) Mittel zur ortsspezifischen alkylierung.
ES2070186T3 (es) Nuevos derivados de 2,4-diamino-pirimidina-3-oxido y su utilizacion en la prevencion de la caida de los cabellos.
ES2011296B3 (es) Derivados de benzo[b]tiofeno y benzo [b]furano carboxamidas, sus procedimientos de preparacion y los medicamentos que los contienen.
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
DK0436435T3 (da) Phenylethanolaminomethyltetraliner og fremstilling deraf samt farmaceutiske midler indeholdende dem
TR199902897T2 (xx) S�v� benz-izo-kuinolin t�revleri.
DK0425209T3 (da) Naphtyloxazolidon Derivater
FI864618A (fi) Nya 3-oxadiazol- och 3-karboksylsyra- -karbolinderivat, deras framstaellning och deras anvaendning som laekemedel.
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
NO995935D0 (no) 17&lt;beta&gt;-allyloksy(tio)alkyl-androstan-derivater for modulering av meiose
CO5251424A1 (es) Oxazinquinolonas utiles en el tratamiento de infecciones virales
ES2117678T3 (es) Derivados de eteres milbemicina, su preparacion y su aplicacion terapeutica y agroquimica.
BR0108845A (pt) 4-hidroxi-1,8-naftiridina-3-carboxamidas como agentes antivirais
AR027035A1 (es) Pirroles sustituidos
DE59800251D1 (de) Fluorierte Alkane und ihre Verwendungen
AU576659B2 (en) 5-sulphonamido-1-aryl-pyrazoles
DK280883D0 (da) Organophosphat-derivater, fremgangsmade til fremstilling deraf samt deres anvendelse som midler til bekaempelse af skadelige organismer
KR910021376A (ko) 6-치환된-헥사하이드로벤즈[cd]인돌
CO5241287A1 (es) Procedimientos para preparar compuestos intermedios plaguicidas de tipo arilamina y derivados de arilhidrazina
SE8105297L (sv) Imidazolderivat